Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
Part 3 – Case Discussion & Wrap-up Erin Schenk, MD, PhD, and D. Ross Camidge, MD, PhD, medical oncologists at the University of Colorado Cancer Center, continue to…
Michael Banks, MD, announces the faculty of The Doctor’s Channel’s upcoming Cases in Thoracic Oncology series. Expert faculty Ross Camidge, MD, PhD, and Erin Schenk, MD, PhD, will…
Raj Chakraborty, MD, assistant professor of medicine at Columbia University Irving Medical Center, discusses promising results from current clinical trials for newly diagnosed multiple myeloma. The GRIFFIN trial…
In an interview conducted during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020, Saad Usmani, MD, MBBS, MBA, of the Levine Cancer Institute in…
In an interview recorded during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020, Luciano Costa, MD, PhD, of UAB School of Medicine, Birmingham, AL,…
Brian G. M. Durie, MD, chairman of the board of the International Myeloma Foundation, discusses whether patients with borderline high-risk smoldering myeloma should begin treatment early. Some treatments…
At the first virtual Immunotherapy Patient Summit, Leena Gandhi, MD, PhD, thoracic oncologist at Dana-Farber Cancer Institute, discusses the latest immunotherapy options for patients with lung cancer. Immunotherapy…
In a sequencing study of 82 patients with smoldering multiple myeloma, there were fewer NRAS and FAM46C mutations and with fewer adverse translocations – del(1p), del(14q), del(16q), and…
In a study of 16,331 patients in the California Cancer Registry, 5.7% developed a second primary malignancy more than 1 year after diagnosis. The 10-year cumulative incidence of…
